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Abstract
Background: Cardiac rehabilitation programs (CRP) represent comprehensive interventions that
are typically limited to four months. Following completion of CRP, it appears that risk factors and
lifestyle behaviours may deteriorate. The Extensive Lifestyle Management Intervention (ELMI)
Following Cardiac Rehabilitation trial will investigate the benefits of a randomized intervention to
prevent these adverse changes.
Methods: Patients with ischemic heart disease (IHD) were randomized following a standard CRP
to the ELMI or to usual care. The ELMI program is a case-managed intervention aimed at
individualizing risk factor and lifestyle management based on current treatment guidelines. The
program consists of cardiac rehabilitation sessions, telephone follow-up and risk factor and lifestyle
counselling sessions. Health professionals work with participants using behavioural counselling and
communications with participants' family physicians. Usual care participants return to their family
physicians' care, and come to the study clinic only to undergo annual outcomes assessment. The
primary outcome is change in IHD global risk after four years. Secondary outcomes include
combined cardiovascular events, health care utilization, lifestyle adherence, quality of life and risk
factors.
Results: Over 28 months, 302 men and women were randomized. This represented 29% of the
total population screened. The average age of study participants is 64 years, 18% are women, 53%
have had a previous myocardial infarction, 73% have undergone previous revascularization and 20%
have diabetes mellitus. Ischemic heart disease risk factors for the entire cohort improved
significantly after subjects had gone through previous CRPs. Baseline risk factors, lifestyle
behaviours and medications were similar between the groups.
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Results of the ELMI trial will provide valuable information for the future design of CRPs.
Background
Current cardiac rehabilitation programs (CRPs) employ
pharmacological management, smoking cessation, nutri-
tion, and exercise and behavioural counselling to effec-
tively manage ischemic heart disease (IHD) risk factors
and to promote favourable lifestyle changes. Previous re-
search has demonstrated that CRPs can reduce morbidity
and mortality as well as cost of care. [1–5] Studies such as
the Stanford Coronary Risk Intervention Project (SCRIP)
and the Lifestyle Heart Trial have demonstrated that long-
term lifestyle and risk factor management results in regres-
sion of atherosclerosis and reduction in cardiovascular
events.[3,4] Despite this finding, many North American
programs are of only 3 to 4 months duration, due to budg-
etary and resource constraints, in addition to insurance
coverage limitations. The Multi-fit trial tried to address
this issue by conducting a post-MI nurse case-managed in-
tervention consisting of counselling sessions and tele-
phone follow-up that take place immediately following
patients' cardiac events. The program, however, was not
overwhelmingly successful in demonstrating long-tem
comprehensive effectiveness.[6] Therefore, current CRPs
face the daunting task of teaching life-long risk factor and
lifestyle management within a short time frame.
Lifestyle adherence is difficult to achieve. Based on one re-
port, less than one third of women were exercising the rec-
ommended three times per week within one year of
completing a CRP.[7] Corresponding worsening of risk
factors following completion of a CRP has also been de-
scribed (body mass index [BMI], total cholesterol [TC],
LDL-C and triglycerides [TG] deteriorated in the years fol-
lowing a CRP, with some risk factors reported to be worse
than the pre-CRP values.[8,9]
At the time of the current study's development, no previ-
ous reports had investigated a CRP follow-up interven-
tion. We therefore conducted our own pilot study to
investigate lifestyle adherence and risk factors for six
months following a CRP.[10] Thirty-six men and women
were randomized to either a comprehensive lifestyle and
risk factor intervention or to usual care. After a six-month
intervention of six cardiac rehabilitation exercise sessions
and two telephone follow-up calls, we reported significant
decreases in TC and LDL-C in the intervention group only.
These findings provided the impetus for undertaking the
current Extensive Lifestyle Management Intervention (EL-
MI), a four-year study of 302 men and women with IHD.
We hypothesize that patients with IHD who have been
randomized to the four-year ELMI program following a
standard CRP will decrease their global risk for IHD com-
pared to a similar patient cohort undergoing usual care.
To assess global risk, we will use and individually analyze
two independent global risk scores: the Framingham
(FRA) and the Procam risk scores, which reflect modifia-
ble risk factors such as total cholesterol (TC), HDL-choles-
terol (HDL-C), blood pressure (BP) and smoking.[11,12]
Methods
Recruitment and randomization
Men and women from two identical, hospital-based CRPs
were screened for the study inclusion and exclusion crite-
ria (Table 1). Those patients meeting the study criteria
were asked to provide informed consent at the time of
their exit CRP assessment (approved by the University of
British Columbia and the St. Paul's Hospital Ethics Com-
mittees). The study criteria were designed so that the ma-
jority of those individuals participating in cardiac
rehabilitation would be eligible for the study. Patients
with IHD and other cardiovascular co-morbidities (i.e.,
heart failure, atrial fibrillation, pacemaker, exercise-in-
duced angina, etc.) were included in the study as long as
the investigators believed that these co-morbidities would
not interfere with full participation. Those patients whose
physical conditioning was severely compromised were
not discharged from the preceding CRP and, therefore,
were not considered for the study. Consenting partici-
pants underwent a baseline lifestyle and risk factor assess-
ment (exercise stress test, leisure time physical activity
[LTPA], diet, quality of life, smoking status, blood pres-
sure (BP), lipids, blood sugar, BMI, waist circumference
(WC) and medication assessment).
The randomization was balanced for age (<63 or ≥ 63
years), gender and adjustments in lipid-lowering medica-
tion (part of the initial CRP protocol) at the time of re-
cruitment (prior to randomization). Random group
assignment was conducted by a blinded research associate
using computer-generated variable block randomization.
Participants were randomized to either the ELMI or Usual
Care (UC) groups, as depicted in Figure 1. Due to the na-
ture of the study, participants were not blinded to their
group assignment.
Usual care group
Participants randomized to the UC group were informed
that they would be contacted once per year to schedule
their annual outcome assessment visits. No other contact
is initiated with the UC participants throughout the study.Page 2 of 14
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formed of their results and of the desired targets for the
specific risk factors. A copy of the lab results is sent to the
UC participants' family physicians. Usual Care partici-
pants are instructed to direct any further questions to their
family physician.
Extensive lifestyle management intervention group
Participants randomized to the ELMI group were contact-
ed by the case manager and scheduled for their first CRP
exercise sessions. A copy of the Treatment Algorithms
used in the intervention was mailed to their family physi-
cians for information purposes only (Figure 2). The ELMI
is a case-managed intervention designed so that each par-
ticipant receives some form of contact every month during
the first year of intervention and every other month in the
following three years (Figure 1). This will result in greater
exposure to health care services than usual care and will
allow us to evaluate whether a new model of health serv-
ices delivery yields additional health benefits compared to
usual care practices. The first year of the ELMI consists of
six CRP exercise sessions over the first three months, six
telephone follow-ups and three lifestyle and risk factor
counselling sessions. Thereafter, ELMI participants are
scheduled for lifestyle and risk factor counselling sessions
every six months, interspersed with telephone follow-ups
at two-month intervals for three years. These modes of
contact were chosen based on those used successfully in
previous studies [3,4,6] as well as in our pilot study.[10]
The ELMI program employs the principles of the Transthe-
oretical Model of Change[13] and the Social Cognitive
Theory.[14] During the CRP exercise sessions as well as
during telephone follow-up calls and lifestyle and risk fac-
tor counselling sessions, each participant's stage of change
is assessed prior to appropriate stage-based counselling.
Participants are counselled on the positives of changing or
maintaining a desired behaviour and are advised about
the use of individual goal setting, based on readiness to
change, personal experience and environment.
The six cardiac rehabilitation exercise sessions (once per
week for four weeks and once per month for two months)
are monitored by the case manager and by an exercise
leader. Each session consists of a warm up, a medically
prescribed target heart rate aerobic exercise, and a cool
down period (approximately 75 minutes). During these
sessions, participants are counselled and given guidance
on how to establish a home-based exercise program. Each
participant receives an ELMI Participant Manual at the on-
set of the exercise sessions. The manual contains a log-
book for exercise, dietary and medication information to
aid in lifestyle adherence and a timetable for scheduled in-
tervention contacts.
Upon entry to the ELMI and at every lifestyle and risk fac-
tor counselling session (a total of ten), participants receive
an ELMI Lifestyle and Risk Factor Report (Figure 3), de-
signed to educate and empower ELMI participants to as-
sume a greater role in their health care. The Report
summarizes the participants' current lifestyle and risk fac-
tor profiles, their previous profile, current goals, and ideal
risk factor and lifestyle targets. The Report is given to par-
ticipants by the case manager, who explains it in detail
and stresses the importance of managing each risk factor
and lifestyle behaviour. On the reverse side of the Report,
goals, recommendations and motivational comments are
documented. A copy of the Report is forwarded to each
participant's family physician, and, when applicable, to
the cardiologist.
The telephone follow-up calls adhere to a formatted out-
line to 1) identify any new symptoms or change in symp-
toms, 2) follow-up on goal progress and 3) assess and
counsel on exercise, diet, medications, smoking cessation
and diabetes management, where applicable. This format
is similar to that used successfully in our previous pilot
study.[10] The case manager conducting the telephone
follow-up reviews the last contact with the participant (ei-
ther a previous follow-up call or an assessment and coun-
selling visit) and the Lifestyle and Risk Factor Report. At
this time, any previously set goals are discussed, and new
Table 1: Study inclusion and exclusion criteria.
Inclusion Criteria Exclusion Criteria
• Patients with IHD who have completed 
a four month CRP.
• Inability to give informed consent.
• Men and women >18 years of age. • Patients who have difficulty understanding the English language.
• No moving plans or extended trips. • Participation in other research trials.
• Provide informed consent. • Patients currently waiting for a surgical intervention.
• Patients with any other medical condition that would make survival for the duration of the study 
unlikely, interfere with optimal participation or produce a significant risk to the patient.Page 3 of 14
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Diagrammatic outline of the study.
First Year
Six cardiac rehabilitation sessions
Six telephone follow-ups
Three lifestyle & risk factor counselling sessions
Month 12
Lifestyle & risk factor outcome assessment
Second Year
Six telephone follow-ups
Three lifestyle & risk factor counselling sessions
Month 24
Lifestyle & risk factor outcome assessment
Month 48
Final outcome assessment
Month 36
Lifestyle & risk factor outcome assessment
Fourth Year
Six telephone follow-ups
Three lifestyle & risk factor counselling sessions
Third Year
Six telephone follow-ups
Three lifestyle & risk factor counselling sessions
Month 12
Lifestyle & risk factor outcome assessment
Month 24
Lifestyle & risk factor outcome assessment
Month 36
Lifestyle & risk factor outcome assessment
Month 48
Final outcome assessment
Usual Care
Group
Lifestyle Management
Intervention Group
Recruitment and
randomization
Completion of cardiac
Rehabilitation programPage 4 of 14
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Lifestyle and risk factor treatment algorithms utilized during the ELMI lifestyle and risk factor counselling sessions.
Activity Management
Energy Expended from Activity Action
> 2000 kcal per week Maintain monitoring of activity and assessment of program 
adherence.
< 2000 kcal per week Refer to Exercise Specialist for assessment and counselling.
Dietary Management
Dietary Profile Action
Meet requirements of Step One diet. Maintain monitoring of diet and assessment of program adherence.
Do not meet requirements of Step One diet. Refer to dietitian for assessment and counselling.
Weight Management
Body Mass Index Action
20-25 kg/m2 Maintain monitoring of obesity and assessment of program 
adherence.
25-30 kg/m2 Refer to appropriate health professional for assessment and 
counselling.
> 30 kg/m2 1. Refer to appropriate health professional for assessment and 
counselling.
2. Letter to family physician reporting values and recommendation 
on action.
Lipid Management
Serum Lipoprotein Profile Action
LDL-C ≤ 2.6 mmol/L
TG ≤ 2.0 mmol/L
HDL- C ≥ 0.9 mmol/L
Maintain monitoring of lipid profile and assessment of program 
adherence.
LDL-C > 2.6 mmol/L
TG > 2.0 mmol/L
HDL- C <0.9 mmol/L
1. Referred to appropriate health professional for reinforcement of 
lifestyle measures.
2. Adjustment of lipid medications in consultation with family 
physician.
Diabetes Management
Metabolic Level Action
No previous diagnosis of diabetes mellitus 
and optimal levels (fasting glucose 4 to 7 
mmol/l and Hb A1c < 110% normal).
Maintain monitoring of glucose and Hb A1c and assessment of 
program adherence.
Previous diagnosis of diabetes mellitus and 
optimal levels (fasting glucose 4 to 7 mmol/l 
and Hb A1c < 110% normal).
Maintain monitoring of fasting glucose and Hb A1c and 
assessment of program adherence.
Suboptimal levels (fasting glucose 7 to 10 
mmol/l and/or Hb A1c 110 to 140% normal).
1. Referred to appropriate health professional for reinforcement of 
lifestyle measures.
2. Appropriate initiation of oral medications in consultation with 
family physician.
Compromised levels (fasting glucose > 10 
mmol/l and/or Hb A1c >140% normal).
1. Appropriate initiation of oral medications in consultation with 
family physician.
2. Appropriate initiation of insulin in consultation with family 
physician.
Blood Pressure Management
Blood Pressure Treatment
< 120/80 mmHg Maintain monitoring of blood pressure and assessment of program 
adherence.
120/80 to 140/90 mmHg Self-help guide book instructing on importance of hypertension and 
exercise, dietary and drug adherence.
> 140/90 mmHg 1. Self-help guide book instructing on importance of hypertension 
and exercise, dietary and drug adherence.
2. Adjustment of anti-hypertensive medications in consultation with 
family physician.
Smoking Cessation Management
Smoking Status Action
Non-smoker Assess smoking status.
Cessation > 6 months Maintain monitoring of smoking and assessment of program 
adherence.
Cessation < 6 months Stage-matched self-help material.
Relapse/current smoker 1. Stage-matched self-help material.
2. Letter to family physician reporting smoking status and 
recommendation on action.Page 5 of 14
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vailable, a message is left. Up to three unanswered mes-
sages are made before marking the telephone follow-up as
a missed event. For those participants who do not have a
means of receiving a message, the call is not counted as
part of the possible three calls. Returned messages to the
case manager are also not counted in the three possible
calls.
The ELMI lifestyle and risk factor counselling sessions are
conducted by the case manager a total of nine times per
participant over the four-year intervention. Prior to these
sessions, participants are asked to complete the LTPA and
the 3-Day Food Record questionnaires and to undergo a
fasting blood draw (lipid profile, glucose and HbA1c if di-
abetic). The sessions consist of assessment of BP, weight,
WC, symptoms, medications and medication compliance.
Month 6, 12, 24, 36 and 48 assessments also include a
graded exercise stress test. The case manager reviews the
new Lifestyle and Risk Factor Report, provides lifestyle
and risk factor counselling as appropriate, and imple-
ments the ELMI Treatment Algorithms (Figure 2). Addi-
tional counselling from a dietitian, exercise specialist or
smoking cessation nurse is determined from the Treat-
ment Algorithms.
The Treatment Algorithms for the ELMI, derived from cur-
rent guidelines and expert consensus [15–19], are aimed
at bridging the gap between current guidelines and current
practices.[20] For weight, diabetes, lipid and BP manage-
ment, the last category of the Treatment Algorithms dic-
tates that the family physician be contacted by letter
regarding recommendations for intervention. These rec-
ommendations are authorized following consultation be-
tween the case manager and the program cardiologist (the
cardiologist does not meet with the participant). Once the
program cardiologist has been consulted and the letter of
recommendation mailed, participants are asked to contact
their family physicians. This process allows the ELMI to
work within the framework of the health care system, rec-
ognizing the family physician as being the primary care
provider. A copy of the letter is kept in the participant's
chart and reviewed during the next participant contact.
Staff training
The case manager and health care professionals taking
part in the ELMI (dieticians, exercise specialists, nurses,
etc.) were from the St. Paul's Hospital Healthy Heart Pro-
gram CRP. All have had several years' previous experience.
In addition, all staff had previously undergone formal
training in counselling techniques and the stages of
change. A trained research coordinator is responsible for
conducting the annual outcomes assessment for all partic-
ipants.
Outcomes
The primary outcome is the absolute change in global risk
for IHD from baseline to year four between the Usual Care
and ELMI groups. Global IHD risk assessment was select-
ed because it is considered to be superior to any single life-
style behaviour or IHD risk factor, given that it reflects the
multi-factorial nature of IHD.[21,22] Global risk is deter-
mined by using two independent global risk scores: 1) the
Framingham (FRA) risk score (a sum of categorical points
based on age, gender, TC, HDL-C, BP, presence of diabetes
and smoking status)[11] and 2) the Procam risk score (a
regression equation based on age, gender, TC, HDL-C, BP,
presence of diabetes, smoking status, previous family his-
tory and presence of angina).[12] We have chosen to use
two risk scores, since no one single score was felt to be su-
perior to another for secondary prevention; however,
these two scores will be analyzed and interpreted separate-
ly.
While the FRA and Procam risk scores were developed to
predict future risk of disease, their use as an outcome
measure does not rely on the accuracy to predict events
but as an instrument for assessing change in global risk.
Prior to their use in this study, minor modifications were
made to the risk scores, to ease interpretation of changes
in risk. These modifications will not affect how each indi-
vidual risk factor contributes to the final score (i.e., age
will change equally for all participants; therefore, this has
been held constant). For the FRA risk score, age is held
constant, results of variables falling above or below the
highest or lowest point categories for each variable are giv-
en the score of the closest category, ex-smokers <12
months are treated as non-smokers, and those without
previously diagnosed diabetes but with glucose >7.8
mmol/L are scored as diabetics. (This latter cut point was
used to define individuals with diabetes in the original
Framingham cohort.) For the Procam risk score, age is
held constant, family history is recorded at baseline and
carried through to follow-up unchanged, and participants
without previously diagnosed diabetes but with glucose
>6.7 mmol/L were scored as diabetics. (This latter value
was used to define individuals with diabetes in the origi-
nal Procam cohort.)
A number of secondary outcomes will be captured to re-
flect the multi-factorial nature of the intervention. These
include combined cardiovascular events (myocardial inf-
arction, revascularization procedures, hospital admis-
sions of a cardiovascular nature), health care utilization,
cost comparison analysis, lifestyle adherence (physical ac-
tivity, exercise capacity, diet composition, smoking sta-
tus), quality of life measures (stress, illness intrusiveness,
self-efficacy), anthropometric measures (body mass in-
dex, waist circumference), IHD risk factors (lipids, fasting Page 6 of 14
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Lifestyle and Risk Factor Report developed at baseline and during the ten lifestyle and risk factor counselling sessions.Page 7 of 14
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to target.
Assessment methods
Cardiovascular events and health care utilization, identi-
fied through documentation of medical records, will be
linked to the provincial Ministry of Health database. Life-
style variables are captured through questionnaires, which
will be distributed to participants via mail three to four
weeks prior to their next scheduled outcomes assessment.
Participants will be asked to complete the questionnaires
at home and to give them to the research coordinator,
who will review them to ensure that they have been fully
completed.
Physical activity adherence is determined by the 4-week
modified Minnesota LTPA questionnaire.[23] Exercise ca-
pacity, assessed by a symptom-limited treadmill exercise
stress test with continuous 12-lead ECG monitoring, is re-
ported as the maximal metabolic equivalents (METs) at-
tained during the test. This method allows for the capture
of ischemia and silent ischemia, based on ECG changes.
Dietary adherence will be determined from a 3-Day Food
Record [24] and will be analyzed using Nutritionist IV
Diet Analysis software by First Data Bank. Average percent
daily kilocalories (kcal) are recorded for protein, carbohy-
drates, total fat, saturated fat and unsaturated fat. Quality
of life is assessed by the Perceived Stress Scale [25] and the
Illness Intrusive Rating[26], both of which use Likert scor-
ing. Self-efficacy is reported as both a general score and an
exercise-specific self-efficacy score that is based on Likert
scoring. The general self-efficacy questionnaire assesses an
individual's perception of his/her ability to successfully
achieve various health-related behaviours (i.e., diet, exer-
cise, medications, etc.). The exercise-specific self-efficacy
questionnaire assesses an individual's perception of his/
her ability to successfully participate in structured exercise
in the presence of various potential barriers such as in-
clement weather, social occasions, family, etc.
Body mass index is calculated from weight in kg divided
by height in m squared. Waist circumference is measured
directly over the skin (to the nearest 0.1 cm) at the point
of maximal narrowing of the trunk as viewed from the an-
terior position, with the participant standing upright fol-
lowing a normal expiration.[27] A manual
sphygmomanometer is used to determine blood pressure
(mmHg), which is recorded as the average of two meas-
ures taken two minutes apart after five minutes of seated
rest. Smoking status is determined by self-report. Serum
TC, HDL-C, TG and glucose are assessed using standard
methodology.[28] LDL-C is calculated using the Fried-
wald Equation (LDL-C = TC - HDL-C - TG/2.22).[29] The
presence of angina is determined through patient inter-
view, based on standard criteria.[30]
Statistical power considerations
At the time of the study's design, we were unable to project
risk score variability (i.e., standard deviation) in this co-
hort over the selected follow-up period, since no data
were available. We anticipated that 10% of participants
would be lost to follow-up (consistent with follow-up fre-
quencies in other long-term trials [3,31]), leaving 90% of
participants available for assessment of the primary out-
come. Reasons for being lost to follow-up include death,
leaving the geographical area without a forwarding ad-
dress and refusal to participate (either through direct con-
tact or by not responding to repeated contact attempts).
Importantly, lack of compliance is not a reason for with-
drawal from the study. With a sample size of 135 people
in each group, we will be able to detect 0.342 of a standard
deviation of the change between the two groups at a pow-
er of 80% (α = 0.05, two sided, 0.363 of a standard devi-
ation at a power of 90%). Based on data published from
the SCRIP study, we will be able to detect differences in
the mean change of three main contributors to the prima-
ry outcome and individual secondary outcomes as fol-
lows: TC of 0.28 mmol/L, HDL-C of 0.08 mmol/L, and
systolic BP of 3.8 mmHg.[3] Therefore, after increasing
the number randomized to account for the 10% lost to
follow-up, a sample size of 300 participants was deter-
mined a priori, resulting in 150 participants being ran-
domly assigned to each study group.
Data on 'lost to follow-up' participants will be analyzed to
elucidate any relevant characteristics that may differ from
the remainder of the study group. Every effort will be
made to obtain final data on the primary outcome regard-
less of the extent of study participation to that point. All
data for the primary and secondary outcomes will be ana-
lyzed using an intent-to-treat analysis such that partici-
pants will remain in their randomly assigned groups at
final analysis, regardless of actual participation within
that group.
Statistical analyses
Baseline characteristics of the ELMI and UC groups (age,
gender, presence of concurrent disease, diagnosis, lifestyle
behaviours and IHD risk factors and changes to these fac-
tors as a result of the prior CRP) were compared using
Pearson Chi-square tests for categorical factors and inde-
pendent samples t-test for continuous factors. Changes in
IHD risk factors and lifestyle behaviours as a result of the
initial CRP were analyzed for the entire cohort using a
paired samples t-test. Change in smoking status as a result
of the CRP was assessed by the McNemar Chi-square test.
Differences in the primary outcome between the ELMI
and UC groups will be compared by an independent sam-
ples t-test. The two global risk scores will be analyzed and
reported separately. The secondary outcome of combinedPage 8 of 14
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Meier survival plot. Other secondary outcomes that are
continuous variables (health care utilization, IHD lifestyle
and risk factors) will be assessed by independent samples
t-tests. Changes in categorical factors (smoking status and
treat to target) will be assessed by the McNemar Chi-
square test. Fulfillment of the ELMI program and use of
medications will be presented as percentages and qualita-
tive data. While not powered to draw conclusions for sub-
group analyses, women and participants with diabetes
will be analyzed for the purpose of hypothesis generation
using non-parametric tests: the Mann-Whitney U test for
independent samples and the Wilcoxon test for paired
samples.
Data are reported as means ± standard deviations. All sta-
tistical analyses were performed using the SPSS 10.0.07
statistical package for Microsoft Windows. The signifi-
cance level for all tests was set at 0.05 and all t-tests are
two-tailed.
Results
Between January of 1998 and May of 2000, a total of 302
men and women who met the study criteria were recruited
and randomized. Table 2 outlines the results of recruit-
ment from both CRP sites. Approximately 60% of those
patients exiting the CRP met the study inclusion/exclu-
sion criteria. Reasons for eligible men and women refus-
ing to provide consent included: not interested, conflict in
schedule with proposed intervention (i.e., occupation),
possible moving plans/uncertain of future plans, time in
the CRP significantly extended due to medical reasons,
and failure to be in contact after receiving the consent
form. Of those eligible, approximately 49% provided in-
formed consent and were randomized. Therefore, this co-
hort represents 29% of the entire population of patients
who completed the two CRPs during the period of active
recruitment. Those patients who were eligible but refused
consent (n = 320) were no different from those that con-
sented with respect to age, 63.5 ± 10.4 years (p > 0.05) and
gender, 76% male (p > 0.05).
Table 3 summarizes the IHD risk factors of the entire co-
hort before and after participation in the standard 16-
week CRP, which preceded enrollment into this study. All
parameters improved significantly, except for HDL-C and
the proportion of smokers.
Of the 302 participants randomized, 151 were assigned to
the ELMI group and 151 were assigned to the UC group.
Tables 4 through 6 describe the baseline characteristics of
the two groups. The proportion of men and women was
Table 2: Results of recruitment from January, 1998 to May, 2000.
CRP Site 1 CRP Site 2
Patients screened 751 295
Eligible 356 (47%) 266 (90%)
Refused consent 145 (19%) 175 (59%)
Randomized 211 (28%) 91 (31%)
Table 3: Changes to IHD risk factors from entire cohort as a result of CRP participation (n = 302).
Before CRP After CRP
Total cholesterol (mmol/L) 4.71 ± 0.95 4.52 ± 0.87**
LDL-C (mmol/L) 2.75 ± 0.80 2.59 ± 0.72**
HDL-C (mmol/L) 1.13 ± 0.32 1.14 ± 0.30
Triglycerides (mmol/L) 1.83 ± 0.98 1.71 ± 0.89*
TC/HDL-C 4.40 ± 1.25 4.15 ± 1.12**
Blood Pressure (mmHg) 131/76 ± 22/11 127/72 ± 21/10**
Smokers (%) 16 (5%) 12 (4%)
Exercise Capacity (METs) 8.4 ± 2.6 10.0 ± 2.5**
BMI (kg/m2) 28.0 ± 4.0 27.6 ± 4.0**
* p < 0.01 compared to Before CRP (paired samples t-test). ** p < 0.001 compared to Before CRP (paired samples t-test).Page 9 of 14
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ment, proportion of participants with diabetes and those
with previous myocardial infarction (MI). Participants
randomized to the ELMI group had more percutaneous
transluminal coronary angioplasty (PTCA) procedures,
less coronary artery bypass graft (CABG) procedures and
less frequency of IHD family history than those in the UC
group. Age was similar between the two groups. Global
risk scores and all metabolic IHD risk factors were similar
between the ELMI and UC groups. Other IHD risk factors
and lifestyle parameters were also similar between the two
groups, except for BMI and WC, which were significantly
lower in the UC group (Table 6). Changes in IHD risk fac-
tors as a result of previous CRP participation were no dif-
ferent between the two groups (data not shown).
Discussion
The ELMI trial is designed to test a new method of health
services delivery that can be readily used in and adapted
to clinical settings throughout North America. To accom-
plish this, the ELMI incorporates a number of techniques
proven successful in previous studies (case management,
face-to-face visits, telephone follow-ups and incorpora-
tion of proven behavioural strategies)[3,6], in addition to
the Lifestyle and Risk Factor Report, the Treatment Algo-
rithms and close communications with the ELMI partici-
pants' family physicians.
Most of the contact between the case manager and the
ELMI participants will be via telephone. This will allow for
a greater frequency of contacts than would be reasonable
for face-to-face visits, thereby permitting more patients to
be managed by one case manager at any given time. We
estimate that each ELMI participant will receive a mini-
mum of 15 hours and a maximum of 23 hours of direct
intervention contact over four years.
The incorporation of the Lifestyle and Risk Factor Report
will: 1) educate and empower the patient and 2) commu-
nicate patients' progress to their primary care physicians.
Previous literature has revealed that educating and em-
powering patients can lead to increased self-efficacy,
which in turn can lead to successful behaviour
change.[32,33] Delivering this report to the participant's
primary care physician will not only facilitate communi-
cation (sometimes overlooked between specialist pro-
grams and primary care) but has been demonstrated to
assist in the treatment of patients.[34]
A unique aspect of the ELMI trial involves the design and
incorporation of the Treatment Algorithms. These will
provide a consistent management guide across the ELMI,
while recognizing that each individual has a unique at-
tributable risk, thereby allowing appropriate allocation of
resources. Another important aspect of the study relates to
the use of current published clinical treatment guidelines
(the same guidelines that are used in usual care) and the
'hands-off' approach to medication changes. These repre-
sent departures from previous multi-factorial IHD inter-
ventions, in that those studies used treatment targets that
were more aggressive than usual care at the time and pre-
scribed medications directly.[3,35] This method main-
tains optimal patient care by providing the primary care
physician with the support and experience of the cardiol-
ogist, thus helping to reduce the treatment gap.[20,36]
Given that both of the CRPs from which participants were
recruited draw their populations locally, it is possible that
some family physicians may have patients in the ELMI
Table 4: Participant demographics: comparisons between ELMI and UC groups (totals with percentages).
ELMI (n = 151) UC (n = 151)
Men 125 (83%) 124 (82%)
Age (years) 64.8 ± 8.8 63.4 ± 10.2
St. Paul's Hospital CRP 108 (72%) 103 (68%)
Family History 43 (28%) 58 (38%)*
IHD presentation
MI 83 (55%) 77 (51%)
CABG 46 (30%) 62 (41%)*
PTCA 66 (44%) 47 (31%)*
Other IHD indicators 24 (16%) 28 (19%)
Angina 43 (28%) 35 (23%)
Diabetes 26 (17%) 34 (23%)
Post-menopausal 14 (54%) 17 (63%)
* p < 0.05 compared to ELMI group (independent samples t-test).Page 10 of 14
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these family physicians will receive comprehensive up-
dates on their patients in the ELMI group in addition to
possible recommendations from the study cardiologist,
we do not foresee contamination to those patients of the
same physician in the UC group to be a major concern.
The Treatment Algorithms distributed to the ELMI group
participants' family physicians are meant to inform physi-
cians about the nature of the study. Those algorithms that
may require physician intervention are based on current
guidelines that each physician has likely received on pre-
vious occasions from various other sources (British Co-
lumbia Medical Association, pharmaceutical marketing
and medical journals). Recommendations from the pro-
Table 5: Medication use at baseline and year one for the ELMI and UC groups expressed as percent values (with absolute numbers).
Medication ELMI (n = 151) UC (n = 151)
Lipid lowering 87% (131) 80% (121)
β-Blocker 70% (105) 67% (101)
ACE Inhibitor 43% (65) 41% (63)
Calcium Channel Blocker 26% (39) 22% (33)
Diuretic 19% (28) 15% (23)
ASA 89% (135) 84% (127)
Hypoglycemic Agents 13% (19) 17% (25)
Angiotensin Receptor Blocker 5% (7) 3% (5)
Anti-anginal 19% (29) 13% (20)
Hormone Replacement Therapy (% 
women)
19% (5) 26% (7)
Table 6: Baseline comparison of IHD global risk scores between ELMI and UC groups.
ELMI (n = 151) UC (n = 151)
FRA Risk Score 6.6 ± 3.1 6.5 ± 3.2
PROCAM Risk Score (% incidence) 20.0 ± 19.7 17.8 ± 18.5
Total cholesterol (mmol/L) 4.46 ± 0.87 4.59 ± 0.93
LDL-C (mmol/L) 2.53 ± 0.74 2.69 ± 0.74
HDL-C (mmol/L) 1.13 ± 0.31 1.15 ± 0.28
Triglycerides (mmol/L) 1.75 ± 0.94 1.65 ± 0.83
TC/HDL-C 4.15 ± 1.08 4.16 ± 1.17
Glucose (mmol/L) 5.8 ± 1.4 5.8 ± 1.7
Blood Pressure (mmHg) 128/72 ± 21/11 127/72 ± 20/10
Smokers (%) 5 (3%) 7 (5%)
Exercise Capacity (METs) 9.8 ± 2.7 10.0 ± 2.5
LTPA (kcal/week) 3137 ± 2531 2963 ± 2183
BMI (kg/m2) 28.1 ± 4.2 27.0 ± 3.7*
Waist circumference (cm) 95.5 ± 12.8 92.7 ± 11.0*
Diet (% daily kcal)
Protein 19 ± 4 19 ± 4
Carbohydrate 56 ± 9 57 ± 8
Fat 22 ± 7 22 ± 7
Quality of life
Perceived stress 33 ± 7 32 ± 8
Illness intrusive 31 ± 14 31 ± 15
Global Self-efficacy 42 ± 4 42 ± 5
Exercise self-efficacy 66 ± 11 65 ± 13
* p < 0.05 compared to ELMI group (independent samples t-test).Page 11 of 14
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tion for their patients in the ELMI group. These will be
specific to each patient's current condition and medica-
tions and will not be applicable to other patients. To as-
sess the possibility of treatment group cross
contamination within a physician's practice post-study
subgroup analysis will investigate whether the outcomes
of those participants in the UC group whose family physi-
cians also have patients in the ELMI group differ from the
remainder of the UC group participants.
The study inclusion criteria were designed to recruit a co-
hort representative of current CRP populations. The main
inclusion criterion for this study was documented diagno-
sis of IHD. Based on the high percentage of participants
recruited (29% of the entire population and 48% of the el-
igible population), this cohort is representative of a large
portion of the CRP population. Compared to other co-
horts, our population has similar characteristics to that re-
ported in a survey of CRP participants with respect to age,
proportion of previous MI, CABG, and diabetes.[37]
Women were not over sampled in this study and therefore
represent only 17.5% of the randomized study popula-
tion. It has been well documented that women are under-
represented in CRP [38]; even when they do attend CRPs,
they are more likely to drop out than men.[39] This may
account for the low representation of women in the study.
This also places limits on performing subgroup analysis
based on gender.
Since the design of this study, two reports investigating in-
terventions following CRP have been published .[40,41]
In the first study, 40 patients were randomized to a one-
year intervention consisting of either monthly counselling
sessions by a nurse or usual care. At the end of the study,
participants in the intervention group had significantly
lower TC and LDL-C values compared to the usual care
group.[40] This coincided with a significantly greater pro-
portion of intervention participants using lipid-lowering
medications (84% vs. 50%, p < 0.05). The authors con-
cluded that the intervention resulted in greater medica-
tion compliance and lower lipid values.
The second study investigated 31 patients exiting a CRP
who were randomly assigned to either a home-based
maintenance program or to usual care. Patients were fol-
lowed for nine months.[41] The home-based mainte-
nance program consisted of an initial visit to the
participant's home, followed by telephone calls from an
exercise physiologist. The calls were conducted every two
weeks during the course of the study. At the end of the
study, there were no significant differences observed be-
tween the two groups with respect to weight, serum lipids
or exercise capacity. The authors speculated that the lack
of deterioration of risk factors in the usual care group may
have accounted for the lack of significant results. Despite
the recent report of these two studies, their inconsistency
of results, small sample sizes and limited application to
the multi-factorial nature of IHD make the implementa-
tion of the ELMI trial that much more timely.
Since this study begins after completion of a CRP, the
study cohort presents with IHD risk factors and lifestyle
behaviours at, or very close to, the recommended targets.
Given that the study intervention is not as concentrated as
the initial CRP, it is possible that this could affect the abil-
ity to detect a difference between the two groups. Current
literature, however, indicates that risk factors and lifestyle
behaviours decline following completion of a CRP.[7–
9,42] Thus, the intervention is designed to maintain the
gains from the initial CRP, anticipating that participants
in the UC group will become non-adherent to diet, exer-
cise, smoking cessation and medications, resulting in a de-
terioration of their risk factor profile.
A possible limitation of this study may be the use of glo-
bal risk scores as the primary outcome. It is currently ac-
cepted that global risk is superior to the measure and
interpretation of any single risk factor.[15] Using a global
risk score will allow for ease of interpretation of effect, as
it is difficult to interpret contradictory changes of individ-
ual risk factors (for example, BP decreases while LDL-C in-
creases). However, no global risk indicator exists that is
applicable to secondary prevention populations or that
represents an outcome of change in global risk. For this
reason, we have chosen to use two independent global
risk scores to reflect changes in global risk. Although these
risk scores were originally designed to predict future risk
of events, this should not pose a problem, as we will assess
the change in these risk scores rather than their predictive
value.
It is generally accepted that a reduction in either of these
global risk scores is favourable, regardless of the patient
population. Even though other IHD risk factors that are
targeted by the ELMI (obesity, sedentary behaviour and
diet) are not included in the FRA and Procam risk scores,
modification of these factors will exert an indirect affect
on the risk score. In addition, all risk score components
and other IHD risk factors will be analyzed as secondary
outcomes. The collection of cardiovascular events will al-
low for possible validation of these two global risk scores
in a secondary population.
Conclusions
The ELMI trial will investigate an individualized multi-fac-
torial intervention aimed at preventing the deterioration
in lifestyle behaviours and risk factors that occurs follow-
ing a CRP. Recruitment and randomization have resulted
in a cohort of men and women who are representative ofPage 12 of 14
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over 300 men and women and a duration of four years,
completion of the ELMI trial will make it one of the largest
randomized, multi-factorial lifestyle and risk factor inter-
vention studies conducted thus far. To date, no other
study has tested an intervention aimed at preventing the
lifestyle adherence and risk factor deterioration that fol-
low cardiac rehabilitation. If the null hypothesis of the
ELMI trial is disproved, this will have far-reaching impli-
cations for current CRP practices. Conversely, if the null
hypothesis is accepted, this will provide valuable informa-
tion with respect to the long-term durability of CRP.
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